PUK5 ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED-DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT RECIPIENTS IN HUNGARY  by Kósa, J et al.
A78 Abstracts
PUK3
CLINICAL IMPACT OF NONCOMPLIANCE AFTER RENAL
TRANSPLANTATION
Babarykin D1, Folkmane I2,Adamsone I2, Bicans J2, Rozental R2
1University of Latvia, Riga, Latvia; 2P. Stradins University Hospital, Riga,
Latvia
OBJECTIVES: Noncompliance to immunosuppressive medica-
tion regimens in renal transplant recipients is an important factor
affecting graft survival. The objective of our study was to
examine the prevalence of noncompliance, to verify factors asso-
ciated with this condition as well as to assess the long term
impact of noncompliance on graft survival after renal trans-
plantation in Latvia. METHODS: Noncompliance with medica-
tion and follow-up care was retrospectively evaluated in 311
adult renal transplant recipients (mean age 48.7 ± 14.4 years,
48.2% female, 86.8% primary graft) with at least a 5 year
follow-up period, using self-report questionnaires, clinician
rating, 20% rate of missing outpatient visits and measurement
of the amount of medication that remained unused (on account
of pharmacists’ report of non-received pills). Thus, our patient
compliance data included considerations of natural environment.
Long-term graft and patient outcomes in compliant and non-
compliant patients were acute rejection rate and chronic allograft
dysfunction, graft and patient one, three and ﬁve year survival.
RESULTS: The prevalence of immunosuppressive medication
regimen noncompliance in this patient setting was 6.1% and
prevalence of appointment noncompliance was 7.1%. Noncom-
pliant patients had more acute rejection episodes (P < 0.05) and
chronic allograft dysfunction (P = 0.02). Risk of all cause graft
failure in the noncompliant group was higher—OR 9.3 (95% CI
3.0–28.8; P < 0.001) compared to the compliant group. Graft
survival at one, three and ﬁve years was 88.3%, 81.3% and
75.7%, respectively, for compliant patients and 73.7%, 61.4%
and 37.9% respectively for noncompliant patients (Log Rank
5.09; P = 0.02). The risk factors associated with noncompliance
was younger age (P < 0.05) and a immunosuppressive regimen
with the highest number of pills (P = 0.02. CONCLUSIONS:
Patients’ compliance with medication and follow-up care after
renal transplantation shows long-term clinical beneﬁts. Thus, it
is of utmost importance to develop intervention strategies to
enhance compliance in this population.
PUK4
BUDGET IMPACT ANALYSIS OF MIMPARA AMONG DIALYSIS
PATIENTS IN BELGIUM USING A MARKOV SIMULATION
MODEL
Roze S1, Palmer AJ1, Standaert B2,Van Kriekinge G2
1CORE Center for Outcomes Research, Binningen, Switzerland;
2Amgen n.v, Brussels, Belgium
OBJECTIVE: To demonstrate the impact of Mimpara (MIM), a
drug against secondary hyperparathyroidism (sHPT), on the
dialysis health care budget in Belgium over time. METHODS: A
Markov model was developed to compare cost of dialysis
patients on standard treatment of care (SOC) with patients on
MIM + SOC (add-on model). The model operates in 1/2 year
cycles over 5 years starting with a cohort of 5,400 patients
(prevalence data). Each year new cases were added to the cohort
and a % dropped out due to death or renal transplant. Mortal-
ity risk was calculated from 2-year cohort dialysis database
(CDB) (n = 13,000)1. Patient distributions for sHPT, calcium x
phosphor values, and MIM dosages were taken from phase III
trials for the MIM arm and from the 2-year CDB for the SOC
arm. Patients withdrawing from MIM were treated as SOC
patients. According to CDB 35% of the initial cohort may
receive MIM (= % of sHPT). Drug uptake was 30% in ﬁrst cycle
with 20% increase per added cycle. MIM drug costs were
€3109/year in ﬁrst cycle and €2617/year per added cycle as only
drug responders (85%) remained on study drug. Other treatment
costs were taken from a retrospective cost study in Belgium2
using average daily cost of €214 per dialysis patient, plus €50/day
for sHPT. Annual 3% discount rate was applied. RESULTS:
Cumulative 5-year cost difference of €7.4 million was seen
between SOC- and MIM-arm (<0.4% total cost increase with
MIM). Running the analysis per year, cost savings early in MIM-
treatment were observed due to reduction in treatment costs of
morbidities related to shift from sHPT. Slight increase in treat-
ment costs was seen later on due to observed survival beneﬁt
with MIM. CONCLUSION: Major budget shifts will not be seen
with Mimpara in its approved indication.
PUK5
ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED-
DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT
RECIPIENTS IN HUNGARY
Kósa J1,Yang X2, Kiss É1, Kaló Z1
1Novartis Hungary, Budapest, Pest, Hungary; 2Novartis Pharma AG,
Basel, Switzerland
OBJECTIVE: The objective of this study was to assess the eco-
nomic impact of everolimus with reduced-dose CsA in de novo
renal transplant recipients in the Hungarian health care setting.
METHODS: Analyses of the trial RADB201 found that total
direct medical costs (costs without everolimus, CsA and MMF)
are mostly dependent on key clinical events, i.e., number of days
on dialysis (hemo- and peritoneal), inpatient length of stay (LOS)
due to adverse events (AE) or infection (INF), and episodes of
biopsy proven acute rejection (BPAR). A multivariate regression
model was applied on the RADB-201 database to predict total
direct medical costs based on these clinical events. The obtained
coefﬁcients, adjusted for patient characteristics, were applied to
the clinical data of the RADA-2306 trial, hence predicting the
economic consequences of the reduced CsA dose . We applied
Hungarian unit costs to the entire clinical database. The time
horizon of the analysis was one year. RESULTS: The model pre-
dicted that the incremental cost for one day on hemodialysis and
peritoneal dialysis was HF 134,617 and HF 50,149, one day of
hospitalization due to AE and INF was HF 41,685 and HF
45,231 and the one BPAR event reached HF 523,907, all these
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parameters with p < 0.001. Compared to MMF, reduced-dose of
CsA with everolimus decreased the one-year total direct medical
cost due to major clinical events by HF 1,373,254 and HF
1,387,057 for everolimus 1.5mg and 3.0mg, respectively (see
table) . Adjusted for patient characteristics, the cost savings
become HF 940,380 for everolimus 1.5mg and HF 838,570 for
everolimus 3.0mg. CONCLUSION: The use of reduced-dose
CsA with everolimus 1.5mg in de novo kidney transplant recip-
ients improves transplant outcomes and reduces one-year total
direct medical cost compared to an MMF based strategy.
PUK6
ECONOMIC IMPACT OF EXTENDED-RELEASE TOLTERODINE
VERSUS IMMEDIATE- AND EXTENDED-RELEASE
OXYBUTYNIN AMONG COMMERCIALLY-INSURED PERSONS
WITH OVERACTIVE BLADDER
Ollendorf D1, Jumadilova Z2,Varadharajan S1, Girase P1
1PharMetrics, Inc, Watertown, MA, USA; 2Pﬁzer, Inc, New York, NY,
USA
OBJECTIVES: To examine the economic impact of extended-
release tolterodine (TOL-ER) versus immediate- (IR) or
extended-release (ER) oxybutynin (OXY) in patients with over-
active bladder (OAB). METHODS: This retrospective cohort
study used the PharMetrics Patient-Centric Database to identify
patients diagnosed with OAB who newly started therapy with
TOL-ER, OXY-IR, or OXY-ER between January 2001 and
December 2002. 12-month pretreatment and follow-up periods
were established from the ﬁrst prescription date. TOL-ER
patients were matched to OXY-IR and OXY-ER patients based
on an estimated propensity score for TOL-ER therapy (i.e., prob-
ability of TOL-ER use based on multiple logistic regression). Use
of OAB pharmaceuticals and related medications; use of outpa-
tient and inpatient services related to OAB, infection, depression,
and other conditions; and all corresponding costs were compiled
for 1 year. Costs were compared using Wilcoxon rank-sum tests,
and total health care costs were validated in a multivariate
context using a generalized linear model. RESULTS: A total of
7257 TOL-ER/OXY-ER (80% female) and 5936 TOL-ER/OXY-
IR (72% female) matched pairs were created (mean age, 54y).
Because of matching, demographic and clinical characteristics
between cohorts were not signiﬁcantly different. Costs for ser-
vices related to OAB, infection, and depression were signiﬁcantly
lower for TOL-ER vs. OXY-ER. Total health care costs were also
signiﬁcantly reduced for TOL-ER (mean [SD], $8303 [$18,802])
vs. OXY-ER ($8862 [$18,864], p = 0.0109). Medication costs
were signiﬁcantly higher for TOL-ER ($2791 [$4997]) than for
OXY-IR ($2204 [$3944], p < 0.0001). However, this increase
was offset by reductions in expenses related to conditions includ-
ing infection and depression. Total costs did not differ signiﬁ-
cantly between TOL-ER and OXY-IR. After adjustment for
between-group differences, costs were signiﬁcantly reduced for
TOL-ER patients versus OXY-ER and OXY-IR (p < 0.01). CON-
CLUSION: Patients with OAB initiating therapy with TOL-ER
incurred lower annual health care costs, including nonpharma-
cologic costs related to OAB, infection, and depression compared
with those receiving OXY-IR or OXY-ER.
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DELIVERING TREATMENT EFFECTIVENESS: COSTS AND
PERSISTENCE OF TOLTERODINE IN THE MANAGEMENT OF
OAB IN FIVE EUROPEAN COUNTRIES
Reeves P1, Kopp Z2, Resch A3, Milsom I4, Kelleher C5,Artibani W6
1Fourth Hurdle Consulting Ltd, London, UK; 2Pﬁzer Inc, New York,
NY, USA; 3Pﬁzer Pharma GmbH, Karlsruhe, Germany; 4Sahlgrenska
University Hospital, Göteborg, Sweden; 5Guy’s & St Thomas’ NHS
Trust, London, UK; 6Monoblocco Ospedaliero, Padova, Italy
OBJECTIVES: Overactive bladder (OAB) is associated with both
an economic and quality of life burden. Current management
involves antimuscarinic agents. Extended release formulations
are expected to improve treatment compliance and persistence.
This study explored persistence and impact on OAB related co-
morbidities with two therapies: tolterodine extended release
(TER) and oxybutynin immediate release (OIR) compared to no
active drug treatment (NONE) and associated costs across ﬁve
European countries. METHODS: A decision-analytic model esti-
mated costs and outcomes associated with treatment. A large
case-controlled study was used to estimate the percentage of
patients achieving persistent control, deﬁned as patients still on
therapy after six months. Resource use included drug costs,
physician visits, incontinence pads and the cost of urinary tract
and skin infections. The model estimated the cost per patient
achieving persistent control of OAB. Costs were estimated from
the perspective of health service payers over six months. Sensi-
tivity analyses included variation of the resource use frequency
assumptions, cost inputs, and the time horizon of the analysis.
RESULTS: After six months, the proportion of patients achiev-
ing persistent control was 39% on TER and 9% on OIR. Costs
per patient for TER ranged between €349 (Germany) and €772
(Sweden) and between €177 (Germany) and €693 (Sweden) for
OIR. Compared against NONE, the Incremental Cost-Effective-
ness Ratios (ICERs) for TER were much lower than for OIR.
ICERs of TER vs. OIR ranged between €351 (Sweden) and €822
(Spain). Sensitivity analysis highlighted the model’s sensitivity to
the time horizon, physician costs and persistency rates. Differ-
ences in costs largely reﬂect variation in the proportion of
patients in each country using incontinence pads. CONCLU-
SION: In this model more than twice as many patients achieve
persistent control with TER than with OIR. The model estimated
the cost per patient achieving persistent control would be lower
with TER than with OIR.
PUK8
COST-EFFECTIVENESS OF SCREENING FOR ALBUMINURIA
AND SUBSEQUENT TREATMENT WITH AN ACE-INHIBITOR;A
PHARMACO-ECONOMIC ANALYSIS
Atthobari J1, Boersma C1, Gansevoort R2, De Jong PE2,
De Jong-van den Berg LT1, Postma MJ1
1University of Groningen, Groningen,The Netherlands; 2University
Medical Center Groningen (UMCG), Groningen,The Netherlands
OBJECTIVES: Studies showed secondary prevention of cardio-
vascular (CV) events to be cost-effective, but only few reports
proved cost-effectiveness in primary prevention, in particular
with respect to nephrologic markers such as urinary albumin
excretion (UAE). Our objective was to conduct cost-effectiveness
analysis of screening for albuminuria in general population 
and subsequent ACE-inhibitor treatment to prevent CV-events.
METHODS: Data is derived from the PREVEND-IT (Prevention
REnal and Vascular ENdstage Disease Intervention Trial) and the
PREVEND observational-cohort study. The PREVEND-IT was
a randomised placebo-controlled trial to assess the effects of fos-
inopril 20mg on CV-events in 864 subjects with UAE 15–300
mg/24hr, blood pressure <160/100mmHg and plasma choles-
terol <8.0mmol/L. Evaluation of treatment was based on the
PREVEND-IT; the screening part was primarily based on the
observational data (PREVEND) gathered among trial partici-
pants and beyond. Cost-effectiveness was estimated for the
Dutch population. Cost-effectiveness was expressed in net costs
per life-year gained (LYG) with a 4% discounting rate and (sto-
chastic) sensitivity analysis. Bootstrapping analysis was used to
derive 95% CI for the cost-effectiveness ratio (CER) and thresh-
old probabilities. RESULTS: Patients treated with fosinopril
